| FOA# |
Topic/Title |
Budget |
Deadline |
| RFA-DA-24-018 |
Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional) |
Phase I: $320,000
Phase II: $2,500,000 |
November 10, 2023 |
RFA-ES-23-008 |
Novel Approaches for Developmental Neurotoxicity Testing (R43/R44 Clinical Trial Not Allowed) |
$295,924 (Phase I)
$1,972,828 (Phase II) |
July 7, 2023 |
| RFA-ES-23-005 |
SBIR E-Learning for HAZMAT and Emergency Response (R43/R44 Clinical Trial Not Allowed) |
“$100,000 (Phase I)
$200,000/year (Phase II, 2 years)” “$100,000 (Phase I)
$200,000/year (Phase II, 2 years)” |
July 14, 2023 |
NOT-OD-23-092 |
Notice of Change to Minimum Performance Standards for SBIR and STTR Applicants |
|
As of Feb 23, 2023 |
NOT-OD-23-087 |
Notice of Clarification Regarding Eligibility Information for SBIR/STTR Commercialization Readiness Pilot Program (CRP) |
|
As of Feb 21, 2023 |
NOT-GM-23-033 |
Notice of NIGMS Withdrawal of Participation from PA-22-179 “PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required)” |
|
As of Feb 23, 2023 |
NOT-GM-23-032 |
Notice of NIGMS Withdrawal of Participation from PA-22-177 “PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required)” |
|
As of Feb 23, 2023 |
| RFA-MD-23-003 |
Innovations for Healthy Living – Improving Minority Health and Eliminating Health Disparities (R43/R44 – Clinical Trial Optional) |
$295,000/$1,970,000 |
September 6, 2023 |
| RFA-MD-23-002 |
Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) |
$295,000/$1,970,000 |
September 6, 2023 |
| PAR-23-032 |
Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases from Academic/Non-profit Lab to Marketplace (SBIR [R43/R44] Clinical Trial Not Allowed) |
$300,000 Phase I
$2,000,000 Phase II |
September 05, 2025 |
| PAS-22-196 |
Advancing Research on Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD) (R43/R44 Clinical Trial Optional)PHS 2022-2 Omnibus Solicitation of the NIH and CDC for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) |
$275,766 Phase I $1,838,436 Phase II |
September 6, 2025 |
| RFA-DA-23-021 |
Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 – Clinical Trial Optional) |
$320K,000 (Phase I); $2,500,000 (Phase II) |
February 15, 2025 |
| NOT-NS-22-017 |
Notice of Special Interest: SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed) |
varies by mechanism |
January 7, 2025 |
| NOT-NS-22-017 |
Notice of Special Interest: SBIR Technology Transfer (R43/R44 Clinical Trial Not Allowed) |
varies by mechanism |
January 7, 2025 |
| PA-21-345 |
Administrative Supplements to Promote Diversity in Research and Development Small Businesses-SBIR/STTR (Admin Supp Clinical Trial Not Allowed) |
varies by mechanism |
September 10, 2024 |
| PAR-21-297 |
Notice of Special Interest (NOSI): Advancing Imaging, Device Production, and Clinical Capabilities in Digital Dentistry (R41/R42, R43/R44 Clinical Trial Not Allowed) |
$259,613 for Phase I awards and $1,730,751 for Phase II awards |
September 5, 2025 |
| PAR-21-282 |
Blueprint Medtech: Small Business Translator (U44 – Clinical Trial Optional) |
$500,000 total cost per year for Phase I and up to $1,500,000 total cost per year for the Phase II |
June 21, 2024 |
| PAR-21-247 |
Technology Development for Single-Molecule Protein Sequencing (R43/R44 Clinical Trial Not Allowed) |
$256,580 for Phase I awards and $1,710,531 for Phase II |
June 16, 2023 |
| PAR-21-265 |
NINDS Renewal Awards of SBIR Phase II Grants (Phase IIB) for Clinical Trials and Clinical Research (R44 Clinical Trial Optional) |
$1,710,531 for Phase IIB |
April 6, 2024 |
| PAR-21-266 |
NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required) |
$1,000,000 in total cost for Phase I, with no more than $700,000 total costs in any year, and $4,500,000 total costs for Phase II with no more $1,500,000 in total cost |
April 6, 2024 |
| PAR-21-267 |
NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required) |
$1,000,000 in total cost for Phase I, with no more than $700,000 total costs in any year, and $4,500,000 total costs for Phase II with no more $1,500,000 in total cost |
April 6, 2024 |
| NOT-HD-21-027 |
Notice of Special Interest (NOSI): Navigating Pediatric to Adult Health Care: Lost in Transition |
Varies based on mechanism |
January 8, 2024 |
| NOT-DC-21-003 |
Notice of Special Interest: NIDCD Health Disparities and Inequities Research |
Varies based on mechanism |
May 8, 2024 |
| NOT-AI-21-056 |
Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies |
Varies based on mechanism |
May 8, 2024 |
| PAR-21-226 |
Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R41/R42 Clinical Trial Not Allowed) |
$259,613 Phase I
$1,730,751 Phase II |
September 6, 2024 |
| RFA-NS-21-022 |
Translational Neural Devices (U44 Clinical Trial Optional) |
$1,000,000 per year in Phase I
$1,500,000 per year Phase II. |
February 21, 2024 |
| PAR-21-225 |
Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models (R43/R44 Clinical Trial Not Allowed) |
$259,613 Phase I
$1,730,751 Phase II |
September 6, 2024 |
| NOT-MH-21-230 |
Notice of Special Interest (NOSI): Research on Strategies to Enhance Mental Health Interventions and Services within Employment and Job Training Settings |
Varies based on mechanism |
September 8, 2023 |
| NOT-MH-21-125 |
Notice of Special Interest (NOSI): Translation of BRAIN Initiative Technologies to the Marketplace |
Not specified |
April 5, 2021 – January 5, 2024 |
| NOT-EB-21-001 |
Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health |
$259,613 |
April 5, 2021 – April 6, 2023 |
| PAR-20-128 |
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance (SB1, Clinical Trial Not Allowed) |
$250,000 – $300,000 |
Standard SBIR dates |
| PAR-20-129 |
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1, Clinical Trial Not Allowed) |
varies by IC |
Standard SBIR dates |
| PAR-20-130 |
SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late Stage Development (SB1 Clinical Trial Required) |
varies by IC |
Standard SBIR dates |
| PA-20-260 |
PHS 2020 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed) |
$256,580 Phase I
$1,710,531 Phase II |
Standard SBIR dates |
| PA-20-261 |
PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Required) |
$256,580 Phase I
$1,710,531 Phase II |
Standard SBIR dates |
| PA-20-262 |
PHS 2020-2 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Required) |
$256,580 Phase I
$1,710,531 Phase II |
Standard SBIR dates |
| PA-20-265 |
PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed) |
$256,580 Phase I
$1,710,531 Phase II |
Standard SBIR dates |
| NOT-MH-20-013 |
Notice of Special Interest (NOSI): Mental Health Comorbidities in HIV Prevention and Treatment |
|
|
| NOT-MH-20-020 |
Notice of Special Interest: Stigma or Other Social Determinants of Health (SDOH) in HIV Prevention and Treatment |
|
|
| NOT-MH-20-023 |
Notice of Special Interest (NOSI): Strengthening the HIV Care Continuum |
|
|
| NOT-MH-20-024 |
Notice of Special Interest (NOSI): Implementation Science to Advance the United States HIV Prevention and Treatment Goals and the Global HIV Prevention and Treatment Targets |
|
|
| NOT-MH-20-035 |
Notice of Special Interest: Developmentally Tailored HIV Prevention and Care Research for Adolescents and Young Adults |
|
|
| PAR-18-801 |
Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44 – Clinical Trial Optional) |
$300,000 Phase I
$2,000,000 Phase II |
Standard Dates |
| PAR-20-109 |
Non-Viral Technologies for in vivo Delivery of Genome Editors (R41/R42 Clinical Trial Not Allowed) |
Standard Phase I, II budgets |
Standard SBIR/STTR dates |
| PAR-20-098 |
Non-Viral Technologies for in vivo Delivery of Genome Editors (R43/R44 Clinical Trial Not Allowed) |
Standard Phase I, II budgets |
Standard SBIR/STTR dates |
